Latest Regulatory News

High-Tech Metals Limited has successfully completed a modest capital raise through a non-renounceable entitlement offer, issuing shares at $0.15 each alongside free attaching options. The company now holds discretion over a significant shortfall placement, which could influence its capital structure in the coming months.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Western Yilgarn NL has secured the Cardea 3 Bauxite Project in Western Australia's Darling Range, adding a significant high-grade bauxite asset near its Julimar Project. Historical drilling confirms strong alumina grades and strategic infrastructure access.

Tambourah Metals Ltd has announced a non-renounceable pro-rata entitlement offer to raise approximately $368,000, issuing new shares at $0.02 each with free-attaching options. The capital raise aims to fund exploration projects including Beatty Park Gold and Speewah North.

Estrella Resources has intersected 6.45 meters of massive manganese oxides in its first-ever drillhole in Timor-Leste, confirming the region’s untapped mineral potential and setting the stage for an extensive follow-up drilling campaign.

Koba Resources has announced a non-renounceable entitlement offer to raise approximately $1.14 million, aiming to fund further exploration at its promising Yarramba Uranium Project in South Australia. The offer includes new shares and attaching options, inviting eligible shareholders to participate by late June 2025.

SRJ Technologies is advancing its transformation into a full-scale Asset Integrity Maintenance provider, appointing a new CEO and relocating its global headquarters to Abu Dhabi to anchor its growth in energy and industrial sectors.

Titanium Sands Limited has locked in a $600,000 convertible loan facility from major shareholders to fund environmental studies and progress its Mannar Heavy Mineral Project. This funding milestone follows recent regulatory approvals and marks a critical step forward for the company.

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

Pacific Edge has successfully raised NZ$16 million through an upsized equity placement, surpassing its initial target and setting the stage for a planned NZ$5 million Share Purchase Plan. The funds aim to accelerate clinical and commercial milestones, including regaining Medicare coverage for its cancer diagnostic tests.

EMVision Medical Devices has activated two additional key sites in its pivotal trial for the emu™ bedside brain scanner, advancing its path toward FDA clearance. These new sites join a growing network of leading stroke centres across the US and Australia.

Life360 has announced a $250 million convertible senior notes offering, with an option for an additional $37.5 million, aiming to bolster its balance sheet and support strategic initiatives.